Matthew Yglesias

@mattyglesias ↗

Deleted No

Hibernated Yes

Last Checked March 20, 2021

Created

Tue Feb 02 20:14:35 +0000 2021

Likes

Retweets

Source

Twitter Web App

View Raw Data

JSON Data

View on Twitter

Likely Available

Matthew Yglesias @mattyglesias

The classic pharma/IP issue is that the patent holder wants to maximize profits by charging way more than the marginal price of manufacturing a dose, and fears being undercut on price by other producers. That's not the issue here; more output wouldn't cost Pfizer sales. — PolitiTweet.org

Posted Feb. 2, 2021 Hibernated

Preceded By

Matthew Yglesias @mattyglesias

I would also say that when assessing claims like the quoted one here you should use some common sense, if there really were tons of spare manufacturing capacity and we were only limited by IP why wouldn't Pfizer just license the IP for money? https://t.co/5F9O2wyEt7 — PolitiTweet.org

The vaccine shortage doesn't need to exist. Pfizer and Moderna could share their design with the dozens of other ph… https://t.co/SDdu6Scd5h

Posted Feb. 2, 2021 Hibernated

Followed By

Matthew Yglesias @mattyglesias

What a time it was when were worried mostly about misinformation spreading at supermarket checkout lines. https://t.co/lobmQXayYF — PolitiTweet.org

Posted Feb. 2, 2021 Hibernated